|
Current issue
Archive
Manuscripts accepted
About the journal
Editorial board
Abstracting and indexing
Contact
Instructions for authors
Ethical standards and procedures
Editorial System
Submit your Manuscript
 
|
4/2022
vol. 97 abstract:
Case report
Anti-integrin treatment as an effective alternative for a patient with ulcerative colitis
Ewa Antonina Biegańska
1
,
Karol Rokicki
1
,
Katarzyna Karolewska-Bochenek
2
,
Izabella Łazowska-Przeorek
2
,
Marcin Banasiuk
2
Pediatr Pol 2022; 97 (4): 347-350
Online publish date: 2022/12/30
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Paediatric ulcerative colitis (UC) has a tendency to run in an extensive manner, with frequent exacerbations. As a result, treatment of paediatric patients is a complex process demanding thorough evaluation, careful monitoring, and selection of appropriate medication. We present a case report of UC in an 11-year-old boy diagnosed at the age of 7 years. During 3 years of treatment many therapeutic methods were used, but none brought a long-lasting therapeutic effect. Due to exhaustion of available therapeutic options, off-label treatment with vedolizumab was introduced. Currently, in his 15th month of the therapy, the patient remains in remission. This case, in line with the available literature, indicates that there might be a need to include vedolizumab to the UC standard treatment regimens. Moreover, it should also be considered for inclusion in funding programs of national health insurance companies. It is of a crucial importance for patients because in some cases it remains the last treatment option.
keywords:
ulcerative colitis, vedolizumab, inflammatory bowel diseases, paediatric ulcerative colitis |
POLSKI
